The Atherosclerosis and Lipid Lowering- is there a Need for New Agents*Corresponding Author:
Copyright: © 0 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Statins has substantially reduced CVD events around the world and is recommended as firstlLne therapy for CVD management. However, a need for other lipid-lowering agents, because some patients do not tolerate statins due to adverse events, or cannot reach LDL-C level desired because of high levels of LDL-C, or patients with very high risk cardiovascular events need more intensive reduction therapy [7-9]. Can we pay the benefits of these new agents when statins are eوٴectLve and inexpensive? Zhang et al. reported a meta-analysis study to evaluate the safety and eٹcac\ of anti-PCSK9 antibodies in randomized, controlled trials (RCTs). 7went\five RCTs encompassing 12,200 patients were included. Нe study showing largely no sLJnLficant dLوٴerence between anti-PCSK9 antibodies and placebo (or ezetimibe), except that alirocumab was associated with reduced rates of death (relative risk (RR): 0.43, 95 % CI: 0.19 to 0.96, P=0.04) and an increased rate of injection-site reactions (RR: 1.48, 95 % CI: 1.05 to 2.09, P=0.02)